Fig. 1: MRPL12 is acetylated at Lysine 163.
From: MRPL12 K163 acetylation inhibits ccRCC via driving mitochondrial metabolic reprogramming
A Immunoblot (IB) analysis of Flag-MRPL12 acetylation in HEK293T cells stably expressing Flag-MRPL12, following treatment with deacetylase inhibitors TSA (5 μM, 16 h) and NAM (10 mM, 6 h). Acetylation of MRPL12 was detected using an anti-acetylated lysine antibody. B IB analysis of acetylated MRPL12 in OS-RC-2 and 786-O cells, treated with TSA (5 μM, 16 h) and NAM (10 mM, 6 h) to assess endogenous acetylation levels. C Immunoprecipitation (IP) confirming MRPL12 acetylation in OS-RC-2 and 786-O cells. D Duolink assay verifying MRPL12 acetylation in OS-RC-2 and 786-O cells. Scale bar = 50 µm. E Identification of MRPL12 lysine acetylation modification sites obtained from PhosphoSitePlus, dbPTM and CPLM. F IB analysis of MRPL12 acetylation in OS-RC-2 cells transfected with wild-type (WT) or mutant forms of MRPL12. G Alignment of amino acid sequences surrounding Lys163 in MRPL12 across different species. H Dot blot assay confirming the specificity of the site-specific anti–MRPL12 K163 acetylation antibody. Significance levels: ns, P > 0.05; *P < 0.05; ***P < 0.001; ****P < 0.0001.
